Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by alixx11on Aug 28, 2013 4:49pm
219 Views
Post# 21704490

Financials...

Financials...Someone recently posted how NOX has $ 5 million, but it's unclear whether that's true... A recent article claims that :
NioGold is well setup to continue the project development on its own with $3,785,340 as of last financials.
https://www.visualcapitalist.com/weekly-trends-august-24-2013


As part of today's news release, Iverson stated that :
We look forward to continuing development of the Marban Block Property, targeting the Marban, Norlartic and Kierens deposits, testing new prospective targets, and advancing the economic studies
I question the logic of agressive spending in today's market, and especially if we only have around $ 4 million to sustain ourselves. I believe we should limit spending substantially, which would give us time to bring in another player (like the original deal with ARZ, although we're unlikely to get anything that sweet again).
<< Previous
Bullboard Posts
Next >>